English

Allotment og Share Options

Report this content

Oslo, September 17th 2012: According to the resolution by the General Meeting on 23 May 2011 and 14 August 2012, the Board of Directors in DiaGenic ASA today allotted options to DiaGenic employees. The share options have strike price of NOK 3.25 per share, which is set based on last week weighted share price + 10%. The options have life of 4 years and can be exercised after 3 years.

The following primary insiders have today been allotted options:

  • Paul de Potocki, CEO: 1,000,000 options
  • Magnus Sjögren, CMO: 45,000 options
  • Ruben Ekbråten, CFO: 45,000 options
  • Anders Lönneborg, Research Director: 12,000 options
  • Praveen Sharma, Head of IP : 12,000 options
  • Gisle Grave, Clinical R&D Director: 12,000 options
  • Torbjørn Lindahl, Bioinformatics Manager: 27,000 options
  • Line Røed, Senior Scientist: 12,000 options

Today a total of 1,227,000 options have been allotted, including allotments listed above. After the allotment today, DiaGenic have a total of 1,459,000 options outstanding.

Contact:

Henrik Lund, Chairman of the Board

Telephone: 47 90971219

e-mail: henrik.lund@diagenic.com

About DiaGenic ASA

DiaGenic seeks to create value for patients, partners, and investors by developing innovative and more patient friendly methods for early detection of diseases utilizing DiaGenic’s unique concept. The concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples.

DiaGenic is a world leader in identifying these gene expression signatures in peripheral blood and is focused on the development of biomarkers in the field of Alzheimer’s disease and Parkinson’s disease. DiaGenic’s Alzheimer’s disease development program includes the CE marked diagnostic test ADtect®, for detection of mild to moderate Alzheimer’s disease, and MCItect®which is under development for identifying patients with very early stages of Alzheimer’s disease (prodromal AD).

DiaGenic’s concept is protected through an extensive patent portfolio. DiaGenic promotes its products and services towards leading pharmaceutical, imaging and diagnostic companies. DiaGenic is located in Norway and listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com

Subscribe